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Abstract The primary hormonal regulator of pigmentation is
melanocyte stimulating hormone derived from proopiomelano-
cortin by proteolytic processing. The melanocortin-1 receptor
serves a key role in the regulation of pigmentation. We describe
the identification of the first intron within a melanocortin
receptor. A new melanocortin-1 receptor isoform, generated by
alternative mRNA splicing, encodes an additional 65 amino acids
at the predicted intracellular, C-terminal tail of the melanocor-
tin-1 receptor. When expressed in heterologous cells, the new
spliced form of the melanocortin-1 receptor (melanocortin-1
receptor B) appears pharmacologically similar to the non-spliced
melanocortin-1 receptor. Melanocortin-1 receptor B is expressed
in testis, fetal heart and melanomas.
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1. Introduction
The melanin pigments, black eumelanin and red phaeomel-
anin, are synthesized from tyrosine. Upon exposure to ultra-
violet radiation, eumelanin is protective while phaeomelanin
generates free radicals causing damage in type I (always burn,
never tan) and type II (always burn, slight tan) skin [1^5].
Light-skinned, red-haired individuals fail to tan and are at
risk for ultraviolet radiation damage. These individuals have
predominantly phaeomelanin in their skin and hair with little
eumelanin.
Five melanocortin receptors (MC-1R through 5) have been
described belonging to the G-protein-coupled receptor (GPC-
R) superfamily [6]. Melanocyte stimulating hormone (MSH)
stimulates pigment cells by binding to the MC-1R causing an
elevation of intracellular cyclic AMP (cAMP) which regulates
the tyrosinase activity [7,8]. An increased tyrosinase activity
and subsequent eumelanin synthesis is caused by activation of
MC-1R while a decreased tyrosinase activity and reduced
MC-1R activation produces phaeomelanin [9,10].
We describe the molecular analysis of a new MC-1R iso-
form (MC-1RB) generated by alternative mRNA splicing. The
discovery of MC-1RB adds additional diversity to the MC-R
family and has implications for MC-1R-mediated signalling
events in humans.
2. Materials and methods
2.1. Expressed sequence tag (EST) identi¢cation
GenBank databases [11] were monitored daily using the TFASTA
search program [12] with amino acid sequences from the human MC-
4R.
2.2. Cloning of the MC-R spliced variant (MC-1RB) from human
genomic DNA
Touchdown PCR was performed with sheared human genomic
DNA (0.5 Wg: Clontech, Palo Alto, CA, USA) in a GeneAmp 9700
PCR system (Perkin Elmer, Foster City, CA, USA). Two sense prim-
ers, MC-1R- 5Pfor1 (5P-TCTCACACTCATCGTCCTCTGCCC-3P)
and MC-1R-5Pfor2 (5P-CATCGCCTACTACGACCACGTGGC-3P),
were designed based on the published sequence of human MC-1R
[13,14,18]. The anti-sense primers, MC-1R-3Prev1 (5P-CGCTGCAAG-
GCTGTTGGATGAAGC-3P) and MC-1R-3Prev2 (5P-GTGGGAGT-
AGCTCTTGGCACACAC), were derived from EST AI123000. An
Advantage cDNA PCR kit (Clontech, Palo Alto, CA, USA) was used
in the PCR reactions essentially following the manufacturer’s instruc-
tions. Two exceptions were the addition of 5% DMSO to the PCR
reactions and PCR cycling as described below: (1) 94‡C for 1 min, (2)
¢ve cycles of 94‡C for 30 s, 72‡C for 3 min, (3) ¢ve cycles of 94‡C for
30 s, 70‡C for 3 min, (4) 20 cycles of 94‡C for 30 s, 68‡C for 3 min.
DNA sequencing was performed using Big Dye terminator cycle ready
sequencing reactions (ABI-Perkin Elmer, Foster City, CA, USA) on a
ABI model 377 instrument and analyzed using the Sequencher 3.0
program (Gene Codes, Ann Arbor, MI, USA).
2.3. Cloning of the MC-R spliced variant (MC-1RB) from human
testis mRNA
Reverse transcriptase PCR (RT-PCR) using 1 Wg of testis mRNA
(pool of 25 male caucasians) was performed using the Advantage RT
for PCR kit with MMLV reverse transcriptase (Clontech, Palo Alto,
CA, USA) essentially following the manufacturer’s instructions. PCR
was conducted with the Advantage cDNA PCR kit (Clontech, Palo
Alto, CA, USA) essentially following the manufacturer’s instructions
with the exception of adding 5% DMSO to the PCR reaction (cycling
conditions: 94‡C for 1 min, 60‡C for 2 min, 72‡C for 2 min, 72‡C for
10 min. The forward sense primer utilized (appending EcoRI restric-
tion enzyme site and optimized initiation sequence based on Kozak
rules) was 5P-GATCGAATTCGCCGCCATGGCTGTGCAGGGAT-
CCCAGAGAAG-3P while the reverse antisense primers were 5P-GA-
TCGAATTCCTAGGGGGGCTCCTGCAAACCTG-3P or 5P-GAT-
CGAATTCGTGCCCAGTCTGAGCCTTAGAACCG-3P. Ampli¢ed
products were agarose gel-puri¢ed, digested with EcoRI and ligated
to the mammalian expression vector pcDNA-3.1 (3) (Invitrogen,
Carlsbad, CA, USA).
2.4. Human MC-1RB stable cell line development
All cell culture reagents were purchased from Gibco-BRL, Life
Technologies. CHO cells were grown in complete media (Iscove’s
modi¢ed Dulbecco’s medium, with L-glutamine and 25 mM HEPES
bu¡er supplemented with HT (0.1 mM sodium hypoxanthine, 0.016
mM thymidine), penicillin-streptomycin (100 U/ml penicillin G so-
dium, 100 Wg/ml streptomycin sulfate in 0.85% saline/water), 2 mM
L-glutamine and 10% heat-inactivated fetal bovine serum). Cells were
transfected with SuperFect transfection reagent (Qiagen) as per man-
ufacturer’s recommendations. At 24 h post-transfection, the cells were
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trypsinized and plated as a 2-fold dilution series in 100 cm dishes
containing complete media plus 1 mg/ml geneticin (G418). Resistant
colonies were identi¢ed in about 2 weeks, expanded and assayed for
binding and functional responses to MSH peptides.
2.5. Cell membrane preparation
Cells were rinsed with phosphate bu¡ered saline (PBS) lacking
CaCl2 and MgCl2 (Life Technologies, Gaithersburg, MD, USA)
and then detached with enzyme-free dissociation media (Specialty
Media, Lavellette, NJ, USA). Cells were pelleted at 2800Ug for 10
min. The cell pellet was resuspended in membrane bu¡er (20 mM Tris
pH 7.2, 5 mM EDTA) with 5 Wg/ml leupeptin, 5 Wg/ml aprotinin, 40
Wg/ml bacitracin, 25 Wg/ml Pefabloc (Boehringer Mannheim) and ho-
mogenized with 10 strokes using a motor-driven te£on-coated pestle
in a glass dounce homogenizer at low speed. The resulting cell sus-
pension was centrifuged at 4100Ug, 4‡C, for 20 min. The pellet was
resuspended in fresh membrane bu¡er with protease inhibitors, ali-
quoted, snap-frozen in liquid nitrogen and stored at 380‡C. The
resulting crude membranes were titrated to determine the optimal
level necessary for performing binding studies (see below).
2.6. Melanocortin (MC) radioligand binding assay
Binding reactions (total volume = 250 Wl) contained MBB (50 mM
Tris pH 7.2, 2 mM CaCl2, 1 mM MgCl2), 0.1% BSA, crude mem-
branes prepared from CHO cells expressing the MC-1RB, 200 pM
[125I]NDP KMSH (Amersham, Arlington Heights, IL, USA) and in-
creasing concentrations of unlabelled test compounds dissolved in
DMSO (DMSO ¢nal concentration = 2%). Reactions were incubated
for 1 h without shaking and then ¢ltered through 96 well ¢lter plates
(Packard, Meriden, CT, USA). Filters were washed three times with
TNE bu¡er (50 mM Tris pH 7.4, 5 mM EDTA, 150 mM NaCl), dried
and counted using Microscint-20 in a Topcount scintillation counter
(Packard, Meriden, CT, USA). Non-speci¢c binding was determined
in the presence of 2 WM unlabelled NDP KMSH (Peninsula, Belmont,
CA, USA).
2.7. cAMP functional receptor assay
Receptor-mediated stimulation of cAMP formation was assayed in
stably transfected CHO expressing MC-1RB. Cells expressing MC-
1RB were dissociated from tissue culture £asks by PBS lacking CaCl2
and MgCl2 (Life Technologies, Gaithersburg, MD, USA) and de-
tached following 5 min incubation with enzyme-free dissociation bu¡-
er (Specialty Media, Lavellette, NJ, USA). Cells were collected by
centrifugation and resuspended in Earle’s Balanced Salt Solution
(EBSS) (Life Technologies, Gaithersburg, MD, USA) with additions
of 10 mM HEPES pH 7.5, 5 mM MgCl2, 1 mM glutamine and
1 mg/ml bovine serum albumin. Cells were counted and diluted to
2^4U106/ml). The phosphodiesterase inhibitor 3-isobutyl-1-methyl-
xanthine was added at a concentration of 0.6 mM. Test peptides
were diluted in EBSS with the above additions and 10% DMSO,
0.1 volume of compounds added to 0.9 volume of cells. After room
temperature incubation for 40 min, cells are lysed by incubation at
100‡C for 5 min to release accumulated cAMP. cAMP was measured
in an aliquot of the cell lysate with a cAMP detection assay kit
(Amersham, Arlington Heights, IL, USA). The amount of cAMP
production which results from an unknown compound is compared
to that amount of cAMP produced in response to KMSH which is
de¢ned as a 100% agonist.
Fig. 1. (Top panel) Graphical comparison of MC-1R sequences. The approximate overlap of various nucleotide MC-1R sequences is shown.
GenBank accession numbers are used for dbEST sequences. MC-1RA-m refers to [15] and MC-1RA-c refers to [14]. (Bottom panel) Schematic
representation of the human MC-1R gene. Splice donor and acceptor sites are shown. The gray boxes are representative of the seven trans-
membrane domains denoted by roman numerals. The black boxes represent the two exons separated by an intron and £anked by an untrans-
lated sequence. The nucleotide sequence of the intron is shown in lower case.
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2.8. Northern analysis
Northern blots purchased from Clontech (Palo Alto, CA, USA)
were pre-hybridized (50% formamide, 4UDenhardt’s solution,
5USSPE, 0.1% SDS, 30 Wg/ml sheared salmon sperm DNA) at
32‡C for 2 h followed by hybridization (50% formamide, 10% dextran
sulfate, 4UDenhardt’s solution, 5USSPE, 0.1% SDS, 30 Wg/ml
sheared salmon sperm DNA) at 32‡C overnight. The probes used
were a MC-1RA/MC-1RB exon junction probe which included 100
bp of MC-1RA sequence 5P to the exon boundary and the entire MC-
1RB tail sequence. In a separate probing, the MC-1RB tail probe
(exon II only) was used. The ¢lters were washed at high stringency
(0.1% SSC, 0.1% SDS, 65‡C) and exposed to ¢lm (Kodak X-Omat)
for 1 week at 830‡C.
3. Results and discussion
An EST (dEST database accession # AI123000, deposited
8/18/97) derived from ¢ve normalized and pooled cDNA li-
braries was identi¢ed with a signi¢cant homology score to the
MC-4R amino acid search sequence. However, FASTA
searches against GenBank revealed that EST AI123000 exhib-
ited the highest sequence identity (s 90% DNA level) to the
3P-end of the gene for the human MC-1R. Two additional
ESTs were subsequently deposited (accession # AI187892
from human testis, deposited 10/13/98; accession #AI379405
from melanocyte, fetal heart, uterus normalized and pooled
cDNA) with a similar high sequence identity to the 3P-end of
the human MC-1R gene. Retrospective searching of the
dbEST subset of GenBank identi¢ed two other human ESTs
with a high sequence identity to the human MC-1R: AA43197
(deposited 5/22/97, from human testis mRNA) and AA778295
(deposited 2/5/98, from human fetal heart mRNA). DNA se-
quence veri¢cation of EST AI123000 con¢rmed that it repre-
sented an alternatively spliced form of the human MC-1R
gene, herein termed MC-1RB encoding 382 amino acids.
PCR using human genomic DNA as a template showed the
presence a cryptic 381 bp intron immediately upstream (at the
C-terminal Trp-317 residue) of the TGA stop codon of the
human MC-1R gene (Fig. 1). The nucleotide boundaries de-
scribing this intron conformed to the consensus splice junction
sequences. A conserved consensus splice donor site (A/C)AG/
gt (nucleotides 950-2) was found which forms the ¢rst two
Fig. 2. Nucleotide and deduced amino acid sequence of the MC-1RA and the alternative splice form MC-1RB. The predicted transmembrane
domains are underlined and numbered from 1 to 7.
FEBS 21986 18-5-99
C.P. Tan et al./FEBS Letters 451 (1999) 137^141 139
bases of the Trp triplet codon (Fig. 1) [13]. Also noted was a
conserved consensus splice acceptor site cag/R (nucleotides
1330-2). Formation of this splice junction results from the
donor supplying TG and the acceptor supplying C to form
the triplet codon for Cys (instead of the C-terminal amino Trp
of the MC-1RA). Extended encoding sequence results in a
reading frame encoding an additional 65 amino acids (not
including the Trp-317 to Cys substitution) (Figs. 1 and 2).
To document that the full-length open reading frame (ORF)
encoding MC-1RB was expressed, RT-PCR was conducted
from human testis poly(A) which resulted in the cloning of
the complete ORF, as shown in Fig. 2. The 65 amino acid tail
does not signi¢cantly match any known protein sequence
(Swiss-Prot Database). This is the ¢rst description of an in-
tron and and alternatively spliced mRNA form of a MC-R.
The splice donor site, CTG/gt, is conserved in all 14 species
whose MC-1R sequence is present in the GenBank database.
Further experiments will be necessary to determine if the
splice variant is unique to humans.
Numerous potential polymorphisms have been reported for
the human MC-1RA, generally clustered in TM-1, TM-2, the
second intracellular loop and TM-7 [14^20]. From both
cDNA and genomic templates, we obtained a nucleotide se-
quence which matched the genomic encoding sequence for
MC-1RA as reported in the GenBank data base entry by
Chhajlani and Wikberg [14] through amino acid 316 (exon
1). It is worthy to note that we have found that exon 1 and
exon 2 (containing the 65 amino acid extension) of the human
MC-1R gene are prone to the introduction of PCR artefacts
as both genomic and cDNA templates yielded sequence nu-
cleotide di¡erences using several polymerases. With the excep-
tion of the original papers [14,15] describing the MC-1RA
cloning from a cDNA and genomic library, determination
of the nucleotide sequence of shorter PCR fragments has
been used to characterize potential MC-1RA variants. Using
nucleotide sequence data reported in [14] for exon 1 and
dbEST submissions AI123000 and AI187892 for exon 2 as
benchmarks, we con¢rmed both exon nucleotide sequences
from cDNA and genomic templates and then used a MC-
1RB construct devoid of any amino acid changes for expres-
sion studies.
Preliminary studies using MC-1RB DNA transiently trans-
fected into COS-7 cells indicated that this receptor is able to
bind MC peptides with a high a⁄nity and that this binding
resulted in signalling via cAMP formation (data not shown).
To fully characterize this receptor, we established cell lines
stably expressing the MC-1RB in CHO cells (CHO 1bX).
Cell line 1bX exhibited speci¢c increases in intracellular
cAMP formation evoked by several MC agonists or mixed
agonists/antagonists, including KMSH, MT-II, SHU-9119,
Q2MSH, NDP-KMSH and ACTH (Table 2). In addition, sev-
eral MC-derived peptides potently displaced the binding of
[125I]NDP-KMSH indicating the presence of a high a⁄nity
binding site conferred by MC-1RB expression. Previous stud-
ies [14,15] have documented that activation of the MC-1RA
isoform by MC agonists results in an elevation of the intra-
Fig. 3. Northern blot analysis of MC-1RB expression. Northern
blots purchased from Clontech with 1^2 Wg poly(A) RNA per lane
were hybridized with a MC-1R probe which is non-selective for
both MC-1RA and MC-1RB. The same ¢lters were subsequently
stripped of the non-selective probe (blots were checked for any re-
sidual signal by autoradiographic exposure) and re-hybridized with
a MC-1RB-speci¢c probe. Following each probing, the blots were
washed at high stringency and exposed to a X-ray ¢lm for a week
at 380‡C. A representative Northern blot is shown in which the
only positive signal occurs in melanoma cells. Both hybridization
probes gave the same hybridization pro¢le. Poly(A) mRNAs that
tested negative are amygdala, caudate nucleus, corpus collossum,
hippocampus, whole brain, substantia nigra, thalamus, heart, skele-
tal muscle, colon, thymus, spleen, kidney, liver, small intestine, pla-
centa, lung, peripheral blood leukocytes, pancreas, adrenal medulla,
thyroid, adrenal cortex, testis, thymus and stomach.
Table 1
Human MC1-R allelic variants
Mountjoy
(MC-1RA)
Chhajlani (MC-1RA) Tan
(MC-1RA)
Valverde (MC-1RA) Box (MC-1RA)
D M
T90 S90 S90 S90 A64S, F76Y, D84E, V92M, T95M,
V97I, A103V, L106Q, D294H
V60L, K65N, R67V, V93L, R142H,
R151C, R160W, A299T
P162 R162 R162 R162
R163 Q163 Q163 Q163
A164 A164 R164 R164
Listing of alleles in the literature according to the ¢rst publication on a particular variant [14^16,20]. Amino acid changes for a given residue
are shown as X-residue number-Y. For reference, both Valverde et al. and Box et al. use the Chhajlani et al. GenBank database entry (given
as D above) as their wild-type allele with the exception that A164 is R. M refers to the sequence presented in reference [14]. As noted in the
text, MC1-RB matches Chhajlani’s database entry through amino acid 316.
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cellular cAMP production through the coupling of G-proteins
to activation of membrane-bound adenylate cyclase. The rank
order of potency of the above peptides in eliciting the cAMP
response was MT-IIVSHU9119VNDP-K-MSHsKMSHV
ACTHs Q2MSH. For comparison, literature values are also
given for the human MC-1RA suggesting that the 65 amino
acid C-terminal extension does not signi¢cantly alter the bind-
ing or activation rank order of potency. The above results
indicate that MC-1RB encodes a functional receptor for
MC ligands with similar pharmacological properties to the
MC-1R-A isoform.
To map the expression pattern of MC-1RB, Northern blots
were hybridized separately under high stringency conditions
with a MC-1RB-speci¢c probe and a second hybridization
probe which should detect both MC-1RA and MC-1RB tran-
scripts. The results were identical with only a single hybridiz-
ing species exclusively observed in melanoma cells (Fig. 3),
even after prolonged autoradiographic exposure. MC-1RB is
also expressed in testis and fetal heart, albeit at a lower level
than melanoma cells (RT-PCR results and random cDNA
library screening for the EST database clones). Human MC-
1RA mRNA has been shown to be most highly expressed in
melanocytes [14,15] and is present in the testis using RT-PCR
[21].
There are numerous common polymorphisms in the encod-
ing sequence of the MC-1RA, some of which are correlated
with variation in pigmentation in humans and other mammals
[14^17,20]. It is therefore possible that allelic variation at the
MC-1R locus may a¡ect the pigmentation pro¢le. By exam-
ple, Valverde et al. [17] correlated nine amino acid substitu-
tions on the receptor to varying shades of red hair and fair
skin, while Box et al. [20] showed that MC-1R polymorphisms
are necessary but not always su⁄cient for red hair production
by studying an additional 11 sites of allelic variation (Table 1)
on red-haired twins. The functional signi¢cance of altered
amino acids due to allelic variation at the human MC-1R
locus is presently unclear. A V92 to M variant was shown
to have a V5-fold reduced potency for binding radiolabelled
KNDP-MSH [18] but showed no di¡erence from the wild-type
receptor when assessed for functional coupling to cAMP ele-
vation [22]. Further studies are necessary to determine the role
of the MC-1RB in MC-1R signalling and pigmentation.
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Table 2
Pharmacology of MC-1RB
Peptide IC50 (nM) EC50 (nM)
MC-1RA MC-1RB MC-1RA MC-1RB
MT-II 0.6 0.3 0.2 0.39 (0.07)
SHU-9119 0.7 0.6 NA 0.73 (0.14)
ACTH 2.5 4.8 8 9.1 (1.0)
KMSH 0.2 2.2 2 3.3 (0.09)
NDP-KMSH 0.1 0.7 0.03 0.9 (0.05)
Q2MSH 11.2 463 s 100 12.7 (4.6)
IC50 values were calculated from displacement curves of [125I]NDP-KMSH by linear regression analysis using Prism 2.0 (Graphpad software,
San Diego, CA, USA). EC50 values were calculated from cAMP dose-response curves as above. Values are an average of two (IC50) or four
(EC50 ; S.E.M. is shown in brackets) experiments. Data for MC-1RA are taken from [23^26]. Peptide sequences: K-MSH (SYS-
MEHFRWGKPV), MT-II (nLDHdFRWK; [26]), SHU-9119 (nLDHdFRWK; [27]), Q-MSH (YVMGHFRWDRFG), NDP-KMSH (SYSn-
LEHdFRWGKPV) and L-MSH (AEKKDEGPYRMEHFRWGSPPKD).
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